Broadly similar quality of life by age in localized pancreatic cancer
In a nationwide cohort of 5,217 patients, age was not independently linked to overall survival after treatment for localized pancreatic cancer.
Our read
Populations- Studied:
- Cohort study of 5,217 patients with localized pancreatic cancer, against younger patients
- What changed:
- Older patients reported broadly similar quality of life to younger patients over time
- The catch:
- Uncaptured differences in health or treatment suitability could confound comparisons between age groups
Editor of record: Boris Djordjevic · AgingResearch.News
Among 5,217 people with localized pancreatic cancer, a nationwide observational cohort compared those aged 75 or older with those under 75 during 2015–2023. Patients received surgery, chemotherapy alone or precisely targeted radiation therapy. Researchers assessed quality of life using a questionnaire.
Older patients reported broadly comparable quality of life over time. After surgery, however, they reported less breathlessness at 0–3 months but more fatigue, pain and difficulty with daily responsibilities at 9–12 months. The chemotherapy-only groups showed no quality-of-life differences. Older patients had higher adjusted odds of dying within 90 days after surgery (odds ratio 1.6) and lower adjusted odds of receiving chemotherapy afterward (odds ratio 0.4). Age was not independently linked to overall survival in any treatment group.
Why it matters
For older people with localized pancreatic cancer, the findings support individualized shared decisions about treatment and suggest that age alone should not rule it out.
Caveats
Older and younger patients may have differed in health or suitability for treatment in ways the analysis did not capture. The findings concern people treated for localized pancreatic cancer, not everyone with pancreatic cancer.
The paper
Utrecht University; University Medical Center Utrecht
European Journal of Cancer, May 24, 2026, Open access
Comments
Be the first to comment.